Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...8384858687888990919293...858859»
  • ||||||||||  Value of Being the First Biosimilar Entrant () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2168;    
    Being the first biosimilar to market has an enduring advantage. Of the total biosimilar sales for a given market, the first entrant
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Burden of Disease in Patients With Uncontrolled Gout in the USA () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2154;    
    Of the total biosimilar sales for a given market, the first entrant This retrospective study identified patients considered to have uncontrolled gout (?3 flares within 18 months with accompanying treatment or ?1 pegloticase prescription(s) following gout diagnosis) between June 2011 and May 2020 from a US health plan claims database (IQVIA PharMetrics
  • ||||||||||  Humira (adalimumab) / AbbVie
    Medication Adherence, Persistence, and Treatment Switching in Patients Receiving Advanced Therapies for Rheumatoid Arthritis in Clinical Practice () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2151;    
    Adult patients diagnosed with RA, initiating an AT (index; date of first pharmacy claim for upadacitinib, tofacitinib, baricitinib, adalimumab, etanercept, abatacept, or tocilizumab) with recent TNFi experience (?12 months pre-index), and with continuous insurance enrollment for ?12 months pre- and post-index were included. Overall, treatment adherence was significantly higher, and rates of treatment discontinuation or switching were significantly lower for patients initiating upadacitinib compared with other ATs after recent TNFi treatment.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Evaluation of Real-World Treatment Patterns in Patients With Uncontrolled Gout in the USA () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2134;    
    Overall, treatment adherence was significantly higher, and rates of treatment discontinuation or switching were significantly lower for patients initiating upadacitinib compared with other ATs after recent TNFi treatment. Patients received a median (range) of 2.0 (0.0
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche
    Evidence Gap Analysis of the Burden of Disease in Thyroid Eye Disease () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1754;    
    Including a work outcomes cohort provided valuable insights as migraines impact work-related disability. We identified several gaps in the literature including the lack of standardized diagnostic criteria for TED , the lack of robust long-term data on current TED therapie s, and the need f or additional clinical, humanistic, and economic burden studies in patients with TED.
  • ||||||||||  The Use of Performance-Based Agreements in Common Diseases in EU3 and US () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1381;    
    Although rare diseases and cancers remain the main focus of PBAs, the study results have shown that those mechanisms are also implemented in common diseases. While the prevalence of common diseases is increasing due to population aging, the use of PBAs in both Europe and the US is expected to grow to enable patients access to new therapies, optimize their budget impact, and decrease payer uncertainty.
  • ||||||||||  Adverse Event Costs Associated With Systemic Therapies for Metastatic Colorectal Cancer Previously Treated With Standard Therapies and Biologics in the United States, Italy, Portugal, and Spain () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1140;    
    OBJECTIVES: To compare costs of managing adverse events (AEs) associated with fruquintinib, trifluridine/tipiracil (T/T), regorafenib, and T/T+bevacizumab (T/T+bev) for the treatment of patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor receptor biologic therapy, and, if RAS wild-type, an anti-epidermal growth factor receptor therapy from the payer perspective in the US, Italy, Portugal, and Spain. Fruquintinib was associated with lower AE management costs compared with regorafenib, T/T, and T/T+bev for patients with mCRC previously treated with standard therapies and biologics.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
    Real-World Treatment Patterns, Sequencing, and Unmet Need in Metastatic Colorectal Cancer (mCRC) () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_664;    
    Real-world treatment patterns in mCRC are quite varied in later LOTs and characterized by the utilization of a wide variety of chemotherapy and targeted therapy. Also, minimal use of regorafenib or TAS-102 and substantial recycling of chemotherapies in relapsed/refractory setting was observed in later lines, pointing to a high level of unmet need in this population.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Cost-Effectiveness Analysis of Blinatumomab for Advanced Acute Lymphoblastic Leukemia in Japan () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_621;    
    Applying the willingness to pay threshold of JPY15 million/QALY, blinatumomab was not cost-effective compared to salvage chemotherapy. In the future, it would be necessary to incorporate a cost-effectiveness perspective in the pricing of cancer treatment in Japan.
  • ||||||||||  Determinants of Innovative Drugs' Adoption: Evidence from Lithuania () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_402;    
    Institutional factors and price play a critical role in defining the speed of innovation diffusion in healthcare. Also, data suggests potential geographically defined inequality of Lithuanian doctors
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Economic Evaluation and Healthcare Resource Utilization (HCRU) Among Breast Cancer Patients Treated with Palbociclib: A Systematic Literature Review (SLR) () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_398;    
    One study demonstrated that neither palbociclib nor ribociclib was cost-effective and one study demonstrated a cost-saving profile for palbociclib as compared to ribociclib or abemaciclib...One study reported that cost-effectiveness of everolimus and palbociclib are equivalent... These findings suggest that although there were no observable differences seen between palbociclib and ribociclib regarding HCRU, ribociclib continues to be cost-effective as compared to palbociclib, with drug cost being the major contributor.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Real-World Evidence on Adherence to the First CDK 4/6 Inhibitor (Palbociclib) in Breast Cancer Patients From Romania () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_363;    
    Most patients received combination therapy with letrozole (46%) and exemestane (13%). While high adherence rates were observed among patients treated with palbociclib, it is important to note that the collected data FROM THE Romanian National Health Insurance House were limited, lacking information on potential adverse reactions that might lead to treatment discontinuation.
  • ||||||||||  Pricing Strategies and Trends of FDA Approved NSCLC Therapies From 2018 to 2023 () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_333;    
    We extracted pricing data on 11 FDA approved novel NSCLC therapies (dacomitinib, capmatinib, entrectinib, selpercatinib, tepotinib, sotorasib, amivantamab, adagrasib, brigatinib, lorlatinib, pralsetinib), which are targeted therapies for specific mutations. In our analysis, NSCLC therapies launched at prices comparable to market competition with price increases comparable to inflation.
  • ||||||||||  topiramate / Generic mfg.
    The Remarkable Efficacy of Topiramate in Treating Oscillopsia in Neuromyelitis Optica Spectrum Disorder: A Video Case Report (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_4268;    
    Further work in the larger geographically diverse collaborative cohort will explore the potential impact of race/ethnicity and other sociodemographic factors on early access to NMOSD specialist care and its impact on disease outcomes. Medications such as memantine, gabapentin, and topiramate have been explored for treating oscillopsia in MS patients...Inebilizumab infusion was started after discharge...Topiramate demonstrated efficacy in NMO-associated oscillopsia in our case, along with the case recently published on Neurology reporting dramatic response of oscillopsia to topiramate in a MS patient, suggesting it could be a promising medication for this debilitating condition.
  • ||||||||||  Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
    Matching-adjusted Indirect Comparison of Current Treatments for NMOSD and Evaluation of Long-term Effectiveness (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_4266;    
    Additionally, treatment with inebilizumab yields better results for expected life years and quality adjusted life years compared to either satralizumab or eculizumab. Relative efficacy and discontinuation were the key drivers of the results.
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    An Update on the Interventions for Hereditary Spastic Paraplegia (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3983;    
    HSP treatment is still challenging. More research should be directed to the genetics and the probable biomarkers to aid in the establishment of more effective treatment.
  • ||||||||||  Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
    Real-world Effectiveness of Intravenous Eptinezumab in Patients with Chronic Migraine and Previous Subcutaneous Preventive Migraine Treatment (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3916;    
    All patients (94/94) self-reported prior preventive therapy with 89% (84/94) reporting prior subcutaneous anti-CGRP mAb use (i.e., fremanezumab, galcanezumab, or erenumab). This real-world, patient survey showed that patients with prior exposure to subcutaneous anti-CGRP mAbs had high overall satisfaction with the effectiveness of eptinezumab treatment regardless of the number and type of previous therapies used.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    An Interesting Presentation of a Blinatumomab-associated Neurological Event (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3507;    
    Ir-AEs include headache, seizures, aphasia, and encephalopathy and are typically managed with infusion interruptions or dexamethasone therapy.Design/Case reportA 39-year-old lady undergoing in-hospital chemotherapy for ALL developed acute onset of global aphasia and right facial droop on day 28 of treatment with blinatumomab prompting activation of a stroke alert...While blinatumomab-induced neurotoxicity was amongst the differentials, due to the focal neurological findings, risk for permanent disability and concern for an acute ischemic stroke, the patient received intravenous therapy with alteplase...An acute neurological change in a patient requires rapid triage and time-sensitive decision making. In patients with cancer who are on immunotherapy with agents such as Blinatumomab, the differentiation of etiologies such as stroke and stroke mimics can be challenging as many of the symptoms of neurologic ir-AEs of Blinatumomab can mimic CVD.
  • ||||||||||  Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
    Downbeat Nystagmus in Patient with AQP4-positive Neuromyelitis Optica (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3461;    
    AQP4-specific T cells are distributed throughout the CNS, with characteristic patterns of increased infiltration in NMO. These regions commonly include the optic nerves and the medulla.NMO involves the brainstem, particularly the area postrema, leading to nausea, vomiting, or hiccups.
  • ||||||||||  The Safety and Efficacy of Dual Calcitonin Gene-related Peptide Therapies for Migraine Treatment (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3206;    
    The observed reduction in headache severity and frequency suggests a dual blockade is beneficial for migraine symptom control in selected patients. Safety regarding this treatment option is also supported by these findings; specifically, the small molecule antagonists appear to be the safest option to include in dual regimens.
  • ||||||||||  Qulipta (atogepant) / AbbVie
    Benefit-Risk Assessment Based on Number Needed to Treat and Number Needed to Harm: Atogepant vs Calcitonin Gene (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3006;    
    The base-case analysis included data from core studies of atogepant 60 mg, erenumab 70 mg and 140 mg, galcanezumab 120 mg, eptinezumab 100 mg and 300 mg, and fremanezumab 225 mg and 675 mg. Atogepant demonstrated a favorable benefit-risk profile, with NNT and NNH values comparable with those of CGRP mAbs across all scenarios.
  • ||||||||||  Qulipta (atogepant) / AbbVie
    Real-world Switching Rates of Atogepant Are Lower than CGRP Monoclonal Antibodies (mAbs) in Patients with Migraine Using Claims Database (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_2727;    
    Patients were excluded if they had ?1 claim for atogepant, rimegepant, BOTOX for migraine, or a CGRP mAb in the 12 months preceding the index date...At 12 months follow-up, 13.4% of atogepant users and 21.1% of CGRP mAb users (23.1% eptinezumab, 26.5% erenumab, 19.6% fremanezumab, 18.4% galcanezumab) initiated a different branded preventive. Compared with atogepant users, CGRP mAb users were significantly more likely to switch to another branded preventive treatment within 1 year of treatment initiation.
  • ||||||||||  Reasons for Discontinuation of Medical Management in Refractory Idiopathic Intracranial Hypertension (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_2471;    
    Our study results suggest that medical management available for IIH may not be suitable for all patients, and many may discontinue the medication due to adverse effects or no improvement in symptoms. IIH patients refractory to medical management are a challenging sub-group requiring invasive and surgical diagnostic and treatment modalities.
  • ||||||||||  Review, Journal, HEOR:  Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario. (Pubmed Central) -  Mar 7, 2024   
    In fact, all extracted studies showed a protective risk factor exposure in monthly migraine days reduction for all the anti-CGRP mAbs, whereas the cost analysis showed that using eptinezumab, in a quarter there is a cost saving of at least $425 per patient, compared with the other anti-CGRP mAbs. With equal efficacy and equal safety, anti-CGRP mAbs should be prescribed also regard to the cost established at the negotiation, making sure to guarantee the best treatment to the patients, but at the same time impacting as little as possible to the healthcare services resources.